Carlos Vergara-Sanchez
Pontificia Universidad Javeriana Cali
Angela Dominguez-Rodriguez
Angiografía de Occidente Cali, Colombia
Judith A Vasquez
Pontificia Universidad Católica Madre y Maestra
Gustavo A Grandez-Castillo
University of San Martin de Porres, University of San Martin de Porres, Lima, Peru.
Ahmed A Elyas
Hamad Medical Corporation
David Hernandez-Herrero
Servicio de Rehabilitacion. Hospital Universitario La Paz. Madrid, Spain
Jennifer C Eaton
Institute for Family Health
Tamar DuBois
Nova Biomedical Inc. Waltham, MA, USA
Andrea Schilling-Redlich
Facultad de Medicina Clinica Alemana -Universidad del Desarrollo, Santiago, Chile
Carolina Ogawa-Matsubayashi
University of Sao Paulo
Amarilis Then-Paulino
Ministerio de Salud Pública, Dominican Republic
Ana Cecilia Scultori S Teles
Hospital Sírio-Libanês
Eduardo Yamaguchi
Universidad de Sao Paulo
Felipe F. Gonzalez
HFAG / IBTS
Johnny Camargo
Instituto de Oncologia do Paraná, brasil.
Marianne Nakai
University of Sao Paulo
Maryam M Aldosari
Primary health care ,Doha, Qatar
Oriol Baptiste-Sainvil
Hospital Metropolitano de Santiago, Dominican Republic
Rafael Augusto Paes-Lima-Rocha
UNIVERSIDADE LÁ SALLE
Renata Meneguetti
Instituto Brasileiro de Controle do Câncer - IBCC, Brasil
Sílvia Corradi Faria de Medeiros
Hospital Evangelico, Brazil
Weiguo Yao
Palleon Pharmaceuticals, Boston USA
Walla Abdalla-Mohamed
Hamad medical corporation
Iona Cosgarea
Translational and Clinical Research Institute, Newcastle University Center for Cancer
Ludmilla Candido-Santos
Massachusetts General Hospital, Harvard Medical School
Yuri Takehara-Chemale
Hospital Municipal e Maternidade Ruth Cardoso - Deltamed
Rami Nassir
Department of Pathology, Faculty of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia
Gelanys Castro-Tejada
Pontificia Universidad Catolica Madre y Maestra
Mayumi Toyama
Kyoto University, Graduate School of Medicine
Olivier F Clerc
University Hospital Basel, Switzerland
Alma Sanchez-Jimenez
Harvard T.H. Chan School of Public Health
Abstract
Introduction: Heart failure affects numerous patients and carries a 50% 5-year mortality rate from the time of diagnosis. Current treatment is based on medication, device therapy and revascularization to reduce morbidity and mortality. However, stem cell therapy could improve cardiac function and outcomes, using a nanogel patch during coronary bypass graft. Methods: An open label phase I/II trial consisting of an initial sentinel approach to test safety, followed by a randomized approach to test efficacy. Discussion: Preclinical studies have shown safety of nanogel patches and clinical trials showed promise using mesenchymal stem cells. New approaches could contribute to the improvement of morbidity and mortality. Mesenchymal stem cell implantation with a nanogel patch could represent an effective and innovative therapeutic approach for patients with heart failure and reduced ejection fraction
